UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO of United Therapeutics) exercised 9,500 stock options and sold 9,500 shares of UTHR common stock held via a trust on August 31, 2026 under a 10b5-1 trading plan.

On August 31, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of common stock, and on the same day sold those 9,500 shares in a series of open-market transactions at weighted average prices between approximately $507.84 and $514.96 per share, generating gross proceeds of roughly $4.84 million. Following these transactions, which were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, the reporting person’s indirect holdings via trusts totaled 324,443 shares (plus additional trust and spouse-related positions disclosed in the footnotes), with the exercised options reducing the trust’s option position by 9,500 shares while still leaving a substantial remaining option balance expiring in 2027.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000132

Alert Tier

6